A detailed history of Great Valley Advisor Group, Inc. transactions in Novo Nordisk A S stock. As of the latest transaction made, Great Valley Advisor Group, Inc. holds 34,905 shares of NVO stock, worth $3.67 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
34,905
Previous 36,856 5.29%
Holding current value
$3.67 Million
Previous $5.26 Million 20.99%
% of portfolio
0.11%
Previous 0.15%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$119.07 - $145.42 $232,305 - $283,714
-1,951 Reduced 5.29%
34,905 $4.16 Million
Q2 2024

Jul 16, 2024

BUY
$122.71 - $146.91 $192,777 - $230,795
1,571 Added 4.45%
36,856 $5.26 Million
Q1 2024

May 03, 2024

BUY
$102.11 - $135.92 $867,220 - $1.15 Million
8,493 Added 31.7%
35,285 $4.53 Million
Q4 2023

Feb 05, 2024

BUY
$87.78 - $105.45 $663,880 - $797,518
7,563 Added 39.33%
26,792 $2.77 Million
Q3 2023

Nov 06, 2023

BUY
$90.94 - $199.54 $1.41 Million - $3.1 Million
15,538 Added 420.97%
19,229 $1.75 Million
Q2 2023

Aug 10, 2023

BUY
$155.98 - $172.65 $222,271 - $246,026
1,425 Added 62.89%
3,691 $597,000
Q1 2023

May 02, 2023

BUY
$132.34 - $159.14 $10,190 - $12,253
77 Added 3.52%
2,266 $360,000
Q4 2022

Jan 31, 2023

BUY
$102.55 - $135.33 $3,384 - $4,465
33 Added 1.53%
2,189 $296,000
Q3 2022

Oct 21, 2022

BUY
$95.28 - $116.93 $285 - $350
3 Added 0.14%
2,156 $215,000
Q2 2022

Jul 19, 2022

BUY
$103.24 - $121.81 $222,275 - $262,256
2,153 New
2,153 $240,000
Q2 2019

Jul 30, 2019

SELL
$46.79 - $52.47 $320,230 - $359,104
-6,844 Closed
0 $0
Q1 2019

Apr 26, 2019

BUY
$46.36 - $52.63 $5,331 - $6,052
115 Added 1.71%
6,844 $358,000
Q4 2018

Apr 11, 2019

BUY
$41.54 - $47.25 $279,522 - $317,945
6,729 New
6,729 $310,000

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $237B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Great Valley Advisor Group, Inc. Portfolio

Follow Great Valley Advisor Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Valley Advisor Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Great Valley Advisor Group, Inc. with notifications on news.